Aurinia Pharmaceuticals (AUPH) Invested Capital (2017 - 2026)

Aurinia Pharmaceuticals has reported Invested Capital for 10 years, with the latest figure at $632.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 50.01% year-over-year to $632.3 million; the trailing twelve-month figure through Mar 2026 stood at $632.3 million (up 50.01% YoY), and the FY2025 full-year result was $650.2 million, up 44.46% from the prior year.
• Invested Capital for Q1 2026 stood at $632.3 million, down from $650.2 million in the prior quarter.
• The five-year high for Invested Capital was $650.2 million in Q4 2025, with the low at $390.4 million in Q1 2023.
• Historically, Invested Capital has averaged $463.4 million across 5 years, with a median of $443.4 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital slipped 15.37% — and 2026, when it soared 50.01%.
• Aurinia Pharmaceuticals' Invested Capital stood at $405.4 million in 2022, then gained by 15.44% to $468.1 million in 2023, then declined by 3.84% to $450.1 million in 2024, then soared by 44.46% to $650.2 million in 2025, then slipped by 2.75% to $632.3 million in 2026.
• The last three Invested Capital figures came in at $632.3 million (Q1 2026), $650.2 million (Q4 2025), and $437.8 million (Q3 2025), per Business Quant data.